Scientists have identified an enzyme whose function is important for the survival of tuberculosis bacteria regardless of whether they are currently dividing or not.
• Immunocore Ltd., of Oxford, UK, said it reached the first milestone in the multitarget research and licensing agreement with London-based Glaxosmithkline plc to develop immunotherapeutics based on its ImmTac monoclonal T-cell receptor technology.
Cytori Therapeutics Inc. shares (NASDAQ:CYTX) headed skyward Tuesday morning after the company disclosed a deal with Chinese firm Lorem Vascular to commercialize Cytori cell therapy in the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia.
LONDON – Midatech Ltd. is poised to move its gold nanoparticle delivery technology into Phase II after raising £10 million (US$16 million) in its first formal round, and attracting Ippon Capital SA as a new investor with a commitment of £7.6 million.
LONDON – A composite molecule that targets the two primary hormones that are released by the gut following meals can reduce weight and lower blood sugar in animal models, raising hopes of new and more effective treatments for obesity and diabetes.
• SRI International, of Menlo Park, Calif., said it was awarded a five-year contract valued up to $9.75 million from the National Institute on Drug Abuse to conduct preclinical safety studies of potential new medicines to treat substance abuse.
• Cel-Sci Corp., of Vienna, Va., said a second interim review of the safety data from its open-label, randomized, Phase III study of immunotherapy candidate Multikine (leukocyte interleukin, injection) was conducted, with the independent data monitoring board recommending that the study continue unmodified.
RSS